Discuss the challenges of enforcing central drug-price notifications through State machinery, especially where hospitals are major suppliers of medicines.

The National Pharmaceutical Pricing Authority (NPPA) works under the Ministry of Chemicals & Fertilizers. It has used Para 19 of DPCO 2013 to cap trade margins on 137 non-scheduled anti-cancer drugs at 30% of MRP [1]. Yet State Drug Controllers enforce the order [1], because health is a State subject. The gap between a central notification and State enforcement decides whether patients actually pay less.

Structural challenges of State-led enforcement

• Split responsibility: the Centre notifies the prices and the States inspect [1]. Where a State gives enforcement less capacity or priority, the order may stay on paper.
• Weak deterrence after the sale: as of 2025, ₹8,526 crore (85%) of NPPA's overcharging demands was unrecovered. About 70% of it is tied up in court, with some cases pending for over 20 years [2]. Penalties imposed after the sale rarely return money to patients.
• Emergency-power basis: TMR still depends on Para 19's extraordinary powers. The Parliamentary Standing Committee found no timeline for a permanent TMR framework in DPCO [2]. This leaves enforcers with one-off orders rather than a standing rule.
• Scale of monitoring: compliance must be checked brand by brand; the 2019 pilot alone covered 526 brands [3]. The 137-drug list will also be "updated periodically" [1], so the target keeps moving.

Hospital-specific challenges

• Direct supply channel: much of the anti-cancer drug supply goes straight to hospitals. Hospitals must therefore charge the revised prices and show them on their websites [1]. Inspections at pharmacy counters cannot easily check bundled or package bills.
• Information gap: a patient in the middle of treatment can rarely check each drug on a hospital bill against Pharma Sahi Daam [1].
• Supply risk: lower margins may tempt suppliers to cut deliveries. The order requires companies to keep production and supply at current levels [1]. However, PIB has reported price cuts, not whether the drugs stayed available [3][4].

Way forward

• Write TMR permanently into DPCO. Create a dedicated NPPA legal cell and a fast-track route for disputes, as the Standing Committee recommended [2].
• Publish brand-level compliance data, as NPPA did in March 2019 (390 of 426 brands showed price cuts) [4]. Add data on supply to hospitals.
• Require hospital bills to list each drug's price, so patients can check them on Pharma Sahi Daam.

Central price notifications help patients only when States enforce them at the point of sale, including hospital billing desks. A permanent legal framework, faster recovery and shared Centre–State compliance data would turn this into cooperative federalism. It would also advance SDG 3.8 (affordable essential medicines) and the right to health under Article 21.